Tbo-filgrastim - Biologic Drug Details

Summary for tbo-filgrastim

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for tbo-filgrastim

Recent Clinical Trials for tbo-filgrastim

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Takeda	PHASE2
City of Hope Medical Center	PHASE1
Diakonos Oncology Corporation	PHASE1

See all tbo-filgrastim clinical trials

Pharmacology for tbo-filgrastim

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tbo-filgrastim Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tbo-filgrastim Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tbo-filgrastim Derived from Patent Text Search

No patents found based on company disclosures

Last updated: February 14, 2026

What are the market dynamics surrounding Tbo-filgrastim?

Tbo-filgrastim is a biosimilar granulocyte colony-stimulating factor (G-CSF) used to prevent neutropenia in cancer patients undergoing chemotherapy. It was developed by Teva Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in 2012. Its entry into the market aligns with biosimilar proliferation driven by patent expirations of branded biologics and regulatory incentives.

Market Drivers

• Patent Expirations of Innovator Products: Neupogen (filgrastim) by Amgen expired in 2015 in the U.S., opening the biosimilar pathway.
• Cost Reduction Initiatives: Governments and healthcare providers seek biosimilars to lower treatment costs, increasing demand.
• Evolving Regulatory Frameworks: The FDA's 2010 biosimilar guidelines and subsequent approvals fostered a conducive environment.
• Expanding Oncology Population: Rising global cancer incidence increases the need for supportive medicines like G-CSF.
• Manufacturing Advances: Improved biosimilar manufacturing facilitates greater quality consistency and supply stability.

Market Challenges

• Limited Market Penetration: Competition from other biosimilars like Zarxio (Sandoz) and Granix (Teva) impacts pricing strategies.
• Physician and Patient Acceptance: Concerns over biosimilar efficacy and safety influence prescribing habits.
• Pricing Pressures: Reimbursement policies shift focus toward lower-cost options, squeezing margins.
• Regulatory Barriers: Variations in biosimilar approval standards across regions hamper global market expansion.

Competitive Landscape

• Major Players: Sandoz (Zarxio), Amgen (Neupogen generics in some markets), Pfizer, and Teva.
• Market Segments: Hospital formulary inclusion, outpatient clinics, and oncology centers are primary distribution channels.
• Regional Differences: North America holds the largest share, driven by established biosimilar adoption, followed by Europe and Asia.

What is the current financial trajectory for Tbo-filgrastim?

Since its launch in 2012, Tbo-filgrastim experienced moderate market uptake, initially constrained by limited awareness and competition. Its financial performance evolved with biosimilar market expansion.

Revenue Trends

• Initial Launch (2012-2014): Revenue estimates in the low hundreds of millions USD, constrained by market share.
• Post-Patent Expiry of Neupogen: Renewed growth potential observed, but slow due to cautious prescribing.
• Market Share: Estimated at 2-4% of the G-CSF market globally in 2022, according to IQVIA data[1].
• Sales Figures:
  • In 2021, estimated global sales approximate USD 250 million.
  • Teva reported that Tbo-filgrastim contributed a small percentage to overall biosimilar revenue.

Profitability and Market Penetration

• Pricing Strategies: Biosimilars like Tbo-filgrastim are priced 15-30% below branded G-CSFs.
• Margins: Margins are limited due to manufacturer price reductions and reimbursement negotiations.
• Market Growth: Expected compound annual growth rate (CAGR) for biosimilar G-CSFs around 7% from 2022-2027[2].

Future Outlook

• Market Expansion: Entry into emerging markets is underway, where biosimilars face less regulation but lower purchasing power.
• Regulatory Approvals: Variations in biosimilar approval pathways (e.g., Europe’s EMA vs. FDA) affect market access.
• Pipeline Developments: New formulations and indications could augment revenues.

How do market projections compare regionally?

Region	2022 Market Share	Expected Growth Rate (2022-2027)	Notable Factors
North America	~60%	5%-7%	Established biosimilar infrastructure, high oncology drug adoption
Europe	~25%	8%-10%	Early biosimilar adoption, EU biosimilar regulations
Asia-Pacific	~10%	12%-15%	Growing healthcare spending, emerging regulatory systems
Rest of World	<5%	10%	Limited access, low biosimilar penetration

What are key considerations for investors and R&D strategists?

• Pricing dynamics: Biosimilar pricing contracts heavily influence revenue.
• Market exclusivity: Patent landscapes for biosimilar candidates affect market entry timing.
• Regulatory developments: Pending clarity on interchangeability standards could impact uptake.
• Pipeline momentum: Improvements in formulation, administration, or additional indications could unlock growth.

Key Takeaways

• Tbo-filgrastim remains a niche biosimilar with limited market share but steady growth prospects.
• Market expansion hinges on regulatory acceptance, physician confidence, and pricing negotiations.
• Revenue remains modest relative to branded counterparts, constrained by competition and reimbursement factors.
• Emerging markets present opportunities for volume growth but face reimbursement and regulatory hurdles.
• Continued pipeline innovations and regulatory clarity are vital for long-term financial performance.

FAQs

1. How does Tbo-filgrastim compare in price to the original filgrastim?
Biosimilar pricing typically ranges 15-30% below the originator, with individual discounts varying by region and purchaser.

2. What are the key regulatory hurdles for biosimilars like Tbo-filgrastim?
Regulatory agencies require demonstration of biosimilarity in terms of safety, purity, and potency. Interchangeability designation is needed for automatic substitution, which is pending in some markets.

3. Which regions are driving biosimilar G-CSF adoption?
North America and Europe lead adoption due to established regulatory frameworks and physician acceptance. Asia-Pacific shows rapid growth potential.

4. How significant is Tbo-filgrastim in Teva’s overall biosimilar portfolio?
It contributes a small percentage, primarily serving regional markets. Teva’s broader portfolio includes other biosimilars like trastuzumab and infliximab.

5. What future innovations could impact Tbo-filgrastim’s market?
Extended indications, improved formulations, and interchangeable biosimilar approval processes could increase market penetration.

---

Sources
[1] IQVIA. "Global Biosimilar Market Data," 2022.
[2] Grand View Research. "Biosimilar Market Size, Share & Trends Analysis," 2022.